Search

Your search keyword '"Croix, Brad St."' showing total 30 results

Search Constraints

Start Over You searched for: Author "Croix, Brad St." Remove constraint Author: "Croix, Brad St." Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
30 results on '"Croix, Brad St."'

Search Results

2. Disruption of anthrax toxin receptor 1 in pigs leads to a rare disease phenotype and protection from senecavirus A infection

3. An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma

5. Abstract LB102: Hexyl-(cuban-1-yl-methyl)-biguanide (HCB) suppresses N-glycosylation of immune checkpoint proteins B7-H3 and B7-H4, reverses tumor hypoxia, decreases intratumoral regulatory T cells, and increases intratumoral CD8+ T cells in the ovarian dependent ER+HER2- SSM2ucd mammary cancer allograft model

13. Supplementary Data from CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

14. Supplementary Data from The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

15. Supplementary Figure 1 from Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor Inhibition

16. Data from Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor Inhibition

17. Cancer cell survival depends on collagen uptake into tumor-associated stroma

19. The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

20. Novel metabolic role for BDNF in pancreatic β-cell insulin secretion

22. Antxr1, Which is a Target of Runx2, Regulates Chondrocyte Proliferation and Apoptosis

24. Abstract C003: Initial testing of m276-PBD CD276 antibody-drug conjugate in preclinical models of pediatric cancers by the Pediatric Preclinical Testing Consortium (PPTC)

25. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

26. Abstract A25: TEM8 specific CAR T cells induce regression of patient-derived xenograft and metastatic models of triple-negative breast cancer

27. Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability

Catalog

Books, media, physical & digital resources